Invokana Lawsuits: Miracle Diabetes Medication or Defective Drug?
Invokana Lawsuits: Miracle Diabetes Medication or Defective Drug?Invokana Lawsuits: Miracle Diabetes Medication or Defective Drug? https://www.cmzlaw.net/wp-content/themes/corpus/images/empty/thumbnail.jpg 150 150 CMZ Law Lufkin/Houston https://www.cmzlaw.net/wp-content/themes/corpus/images/empty/thumbnail.jpg
What are the problems with Invokana?
Since the Judicial Panel on Multidistrict Litigation consolidated federal cases in New Jersey last month, the number of lawsuits involving Invokana, a medication designed to treat Type II diabetes, has risen steadily. By December 15, 2016, 63 cases involving problems with the medication had already been filed; by January 17, 2017, that number had jumped to 100! Attorneys all over the country expect this number to continue climbing.
If you have suffered ill effects from Invokana, you should contact a personal attorney in your state who is experienced in working on cases involving defective drugs. Since drug companies are known to be particularly difficult to fight, it is essential that you have a highly competent personal injury attorney to vigorously defend your rights.
What type of personal injuries are associated with the use of Invokana?
Hundreds of patients have suffered injuries due to their use of Invokana. During the 2 years since Invokana was approved by the FDA, that agency has received over 100 reports of serious kidney damage. This led to stronger warnings of
- Heart attack
- Respiratory failure
- Diabetic ketoacidosis
Four patients have died after being hospitalized for adverse reactions to Invokana, two of them as a result of heart attacks. Invokana lawsuits are being brought to court on behalf of loved ones whose deaths were due to reactions to the drug. Cynthia Freeman, whose husband died at the end of 2016, filed a lawsuit on behalf of him and herself against Janssen Pharmaceuticals Inc., a subsidiary of Johnson & Johnson that markets Invokana in the United States.
The Freeman lawsuit alleges that Janssen has concealed, and continues to conceal, its awareness of “unreasonably dangerous” risks connected to Invokana. The suit asserts that Janssen failed to warn the public about the drug’s risk, and engaged in negligence and fraud when marketing the product